A Prospective Sub-Study of the Global Hypophosphatasia Registry

Study Identifier:
ALX-HPP-501s
ClinicalTrials.gov Identifier:
NCT05234567
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Asfotase Alfa
Date
Aug 2022 - Jul 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Any age or sex with a confirmed diagnosis of pediatric-onset HPP (that is, first HPP sign or symptom presented at \< 18 years of age).
  • Currently receiving asfotase alfa treatment at Enrollment (not treatment-naïve) or the Physician has decided to resume (not treatment-naïve) or start (treatment-naïve) the participant's asfotase alfa treatment within 6 months after Enrollment.
  • Participant must have documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, and a documented ALPL gene mutation (Note: An exception is made for infants with clinical features of HPP plus low ALP who need to start asfotase alfa treatment right away, at the Physician's discretion, but do not yet have a genetic result. In this case, ALPL gene documentation is not required at the time of sub-study enrollment but should be documented within 6 months after Enrollment).
  • Participant or participant's parent/legally authorized representative is able to read and/or understand the informed consent and study questionnaires in the local language.
  • Participant or participant's parent/legally authorized representative must be willing and able to give signed informed consent for this sub-study, and the participant must be willing to give written informed assent, if appropriate and required by local regulations.
Exclusion Criteria
  • Currently participating in an Alexion-sponsored interventional clinical study. Participants who have concluded participation in an Alexion-sponsored asfotase alfa clinical study are eligible to enroll in this sub-study.
Sex
Female & Male
Age
N/A

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Asfotase Alfa
Date
Aug 2022 - Jul 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Any age or sex with a confirmed diagnosis of pediatric-onset HPP (that is, first HPP sign or symptom presented at \< 18 years of age).
  • Currently receiving asfotase alfa treatment at Enrollment (not treatment-naïve) or the Physician has decided to resume (not treatment-naïve) or start (treatment-naïve) the participant's asfotase alfa treatment within 6 months after Enrollment.
  • Participant must have documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, and a documented ALPL gene mutation (Note: An exception is made for infants with clinical features of HPP plus low ALP who need to start asfotase alfa treatment right away, at the Physician's discretion, but do not yet have a genetic result. In this case, ALPL gene documentation is not required at the time of sub-study enrollment but should be documented within 6 months after Enrollment).
  • Participant or participant's parent/legally authorized representative is able to read and/or understand the informed consent and study questionnaires in the local language.
  • Participant or participant's parent/legally authorized representative must be willing and able to give signed informed consent for this sub-study, and the participant must be willing to give written informed assent, if appropriate and required by local regulations.
Exclusion Criteria
  • Currently participating in an Alexion-sponsored interventional clinical study. Participants who have concluded participation in an Alexion-sponsored asfotase alfa clinical study are eligible to enroll in this sub-study.

Protocol Summary

In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.

Trial Locations

Location
Status
Location
Clinical Trial Site
Hartford, Connecticut, United States, 06106
Status
Recruiting
Location
Clinical Trial Site
Chicago, Illinois, United States, 60611
Status
Recruiting
Location
Clinical Trial Site
Boston, Massachusetts, United States, 02122
Status
Recruiting
Location
Clinical Trial Site
Kansas City, Missouri, United States, 64108
Status
Recruiting
Location
Clinical Trial Site
Mineola, New York, United States, 11501
Status
Recruiting
Location
Clinical Trial Site
Cincinnati, Ohio, United States, 45229
Status
Not yet recruiting
Go to page